Targeting the Uncommon: A Case Report of Osimertinib Response in Advanced NSCLC Patient with Dual EGFR (E701fs and L702fs) Frameshift Deletions

Non-small cell lung cancer (NSCLC) accounts for approximately 85% of lung cancers with adenocarcinoma being the most common subtype. Patients with stage IV NSCLC typically have poor prognosis. In these patients, identification of actionable genomic alterations allows for the selection of targeted th...

Olles dieđut

Bibliográfalaš dieđut

Váldodahkkit:	Angel Kwan Qi Wong, Saqib Raza Khan, Danial Khan Hadi, Daniel Breadner, Mark David Vincent
Materiálatiipa:	Artigo
Giella:	Inglês
Almmustuhtton:	MDPI AG 2026-01-01
Ráidu:	Current Oncology
Fáttát:	non-small cell lung cancer EGFR mutation uncommon mutation osimertinib OCELOT clinical trial
Liŋkkat:	https://www.mdpi.com/1718-7729/33/1/55
Fáddágilkorat:	Lasit fáddágilkoriid Eai fáddágilkorat, Lasit vuosttaš fáddágilkora!